Australia markets open in 7 hours 22 minutes

Angion Biomedica Corp. (ANGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.2600+0.0300 (+2.44%)
As of 12:36PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 38.35M
Enterprise value -30.44M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.29
Price/book (mrq)0.57
Enterprise value/revenue -1.03
Enterprise value/EBITDA 0.92

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-91.74%
S&P500 52-week change 3-6.07%
52-week high 316.0350
52-week low 31.0750
50-day moving average 31.7227
200-day moving average 34.5708

Share statistics

Avg vol (3-month) 392.3k
Avg vol (10-day) 3119.16k
Shares outstanding 529.96M
Implied shares outstanding 6N/A
Float 820.66M
% held by insiders 132.60%
% held by institutions 121.94%
Shares short (12 May 2022) 4793.47k
Short ratio (12 May 2022) 47.29
Short % of float (12 May 2022) 43.11%
Short % of shares outstanding (12 May 2022) 42.65%
Shares short (prior month 13 Apr 2022) 4540.8k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin -108.57%
Operating margin (ttm)-103.60%

Management effectiveness

Return on assets (ttm)-17.38%
Return on equity (ttm)-40.25%

Income statement

Revenue (ttm)29.59M
Revenue per share (ttm)0.99
Quarterly revenue growth (yoy)344.20%
Gross profit (ttm)-20.82M
EBITDA -30.54M
Net income avi to common (ttm)-32.13M
Diluted EPS (ttm)-1.0750
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)73M
Total cash per share (mrq)2.44
Total debt (mrq)4.43M
Total debt/equity (mrq)6.60
Current ratio (mrq)7.34
Book value per share (mrq)2.24

Cash flow statement

Operating cash flow (ttm)-55.74M
Levered free cash flow (ttm)-17.75M